Hepatitis B: Treatment to prevent perinatal transmission

Clinical Obstetrics and Gynecology

Volumn 55, Issue 2, 2012, Pages 541-549

  Tran, Tram T ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HBIG; Hepatitis B; lamivudine; pregnancy; tenofovir; vaccination

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ABSENCE OF SIDE EFFECTS; ANTIVIRAL THERAPY; ARTICLE; BIRTH DEFECT; CLINICAL ASSESSMENT; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG DIFFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS B; HUMAN; IMMUNIZATION; IMMUNOPROPHYLAXIS; LIVER HISTOLOGY; MOTHER TO CHILD TRANSMISSION; PERINATAL DRUG EXPOSURE; PREGNANCY; PUERPERIUM; RISK REDUCTION; TREATMENT DURATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNOTHERAPY, ACTIVE; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 84860307632     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0b013e318251097a     Document Type: Article

References (48)

1. Gambarin-Gelwan M. Hepatitis B in pregnancy. Clin Liver Dis. 2007;11: 945-963. (Pubitemid 350019024)
2. Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol. 2003;39 (suppl 1):S64-S69. (Pubitemid 37222649)
3. Tran T. Hepatitis B and pregnancy. Curr Hepat Rep. 2009;8:154-156.
4. Jonas M. Hepatitis B and pregnancy: An underestimated issue. Liver Int. 2009;29 (suppl 1):133-139.
5. Gupta I, Ratho RK. Immunogenicity and safety of two schedules of Hepatitis B vaccination during pregnancy. J Obstet Gynaecol Res. 2003;29:84-86. (Pubitemid 36575542)
6. Tran TT, Keeffe EB.Management of the pregnant hepatitis B patient. Curr Hepat Rep. 2008;2:43-48.
7. World Health Organization. Hepatitis B. World Health Organization fact sheet 204. Available at: Http://who.int/inf-fs/en/fact204.html. Accessed December 20, 2011.
8. Centers for Disease Control and PreventionImplementation of newborn hepatitis B vaccination-worldwide, 2006. MMWR Morb Mortal Wkly Rep. 2008;57:1249-1252.
9. del Canho R, Grosheide PM, SchalmSW, et al. Failure of neonatal hepatitis B vaccination: The role of HBV-DNA levels in hepatitis B carrier mothers and HLA antigens in neonates. J Hepatol. 1994;20: 483-486. (Pubitemid 24146362)
10. Wiseman E, Fraser MA, Holden S, et al. Perinatal transmission of hepatitis B virus: An Australian experience. Med J Aust. 2009;190:489-492.
11. Ngui SL, O'Connell S, Eglin RP, et al. Low detection rate and maternal provenance of hepatitis B virus S gene mutants in cases of failed postnatal immunoprophylaxis in England and Wales. J Infect Dis. 1997;176:1360-1365. (Pubitemid 27461004)
12. Lee SD, Lo KJ, Tsai YT, et al. Maternal hepatitis B virus DNA in mother infant transmission. Lancet. 1989;1:719.
13. Karthigesu VD, Allison LM, Ferguson M, et al.Ahepatitis B virus variant found in the sera of immunised children induces a conformational change in the HBsAg ''a'' determinant. J Med Virol. 1999;58:346-352. (Pubitemid 29326047)
14. US Food and Drug Administration. Code of federal regulations. Title 21. Volume 4, Part 201-Labeling. Revised April 2009. Available at: Http://www.accessdata.fda. gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm ?fr5201.57. Accessed November 28, 2009.
15. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B. J Hepatol. 2009;50:227-242.
16. Lok AS, McMahon BJ. Practice Guideline Committee, American Association for the Study of Liver Disease, AASLD Practice Guidelines. Chronic Hepatitis B: Update 2009. Hepatology. 2009;50: 661-662.
17. Keeffe EB, DieterichDT, Han SB, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin GastroenterolHepatol. 2008;6:1315-1341. [quiz 1286].
18. Fontana RJ. Side effects of long-T erm oral antiviral therapy for hepatitis B. Hepatology. 2009;49 (suppl 5):S185-S195.
19. U.S. Preventive Services Task Force. Screening for hepatitis B virus infection in pregnancy: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2009; 150:869-873. W154.
20. Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57:1-20.
21. ACOG Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin No. 86: Viral hepatitis in pregnancy. Obstet Gynecol. 2007;110:941-955.
22. Ornoy A, Tenebaum A. Pregnancy outcome following infections by coxsackie, echo, measles, mumps, hepatitis, polio, and encephalitis virus. Reprod Toxicol. 2006;21:446-457.
23. Liaw YF, Leung N, Kao JH, Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update. Hepatol Int 2008;2:263-283.
24. XuD, Yan Y, Choi BC, et al. Risk factors and mechanism of transplacental transmission of hepatitis B virus: A casecontrol study. J Med Virol. 2002;67: 20-26. (Pubitemid 34260071)
25. Lin HH, Lee TY, Chen DS, et al. Transplacental leakage of HBeAg-positive maternal blood as the most likely route in causing intrauterine infection with hepatitis B virus. J Pediatr. 1987;111:877-881.
26. Burk RD, Hwang LY, Ho GY, et al. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J InfectDis. 1994;170:1418-1423. (Pubitemid 24369900)
27. Pande C, Kumar A, Patra S, et al. High maternal hepatitis virus DNA levels but not HBeAg positivity predicts perinatal transmission of hepatitis B to the newborn. Gastroenterology. 2008;134:A-760.
28. Su G, Pan K, Zhao N, et al. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol. 2004;10:910-912. (Pubitemid 38418373)
29. Tang JR, Hsu HY, Lin HH, et al. Hepatitis B surface antigenemia at birth: A long- term follow-up study. J Pediatr. 1998;133:374-377.
30. del Canho R, Grosheide PM, Mazel JA, et al. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: Protective efficacy and longterm immunogenicity. Vaccine. 1997;15: 1624-1630. (Pubitemid 27445742)
31. Ip HM, Lelie PN, Wong VC, et al. Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA. Lancet. 1989;1: 406-410. (Pubitemid 19059152)
32. Connor EM, Sperling RS, GelberR, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180. (Pubitemid 24331334)
33. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral pregnancy registry international interim report for 1 January 1989 through 31 July 2011. Wilmington (NC): Registry Coordinating Center; 2011. Available at: Http://www.APRegistry.com. Accessed Dec 10, 2011.
34. Dybul M, Fauci AS, Bartlett JG, et al. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations on the Panel on Clinical Practices for the Treatment of HIV. MMWR Recomm Rep. 2002;51: 1-55.
35. Han GR, Cao MK, Zhao W. A prospective and open label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol. 2011;55:1215-1221.
36. Peters MG. Special populations with hepatitis B virus infection. Hepatology. 2009;49 (5 suppl):S146.
37. Lok AS, Fleischer R, Liang TJ, et al. Management of hepatitis B: Summary of a clinical research workshop. Hepatology. 2007;45:1056-1075. (Pubitemid 46646501)
38. Tyrell DJL, Mitchell MC, De Man RA, et al. Phase II trial of lamivudine for chronic hepatitis B. Hepatology. 1993;18:112A.
39. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet. 2004;43:1071-1087. (Pubitemid 40013177)
40. Johnson MA,Moore KH, Yuen GJ, et al. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999;36:41-66. (Pubitemid 29056000)
41. van Zonneveld M, vanNunen AB,Niesters HG, et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat. 2003;10:294-297. (Pubitemid 36801916)
42. Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: A multicentre, randomized, double- blind, placebo-controlled study. J Viral Hepat. 2009;16:94-103.
43. Chotiyaputta W, Lok AS. Role of antiviral therapy in the prevention of perinatal transmission of hepatitis B virus infection [editorial]. J Viral Hepat. 2009;16:91-93.
44. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341:1256-1263. (Pubitemid 29489740)
45. ter Borg MJ, Leemans WF, de Man RA, et al. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat. 2008;15:37-41. (Pubitemid 350243581)
46. Tran T. Management of hepatitis B in pregnancy: Weighing the options. Cleve Clin J Med. 2009;76 (suppl 3):S25-S29.
47. Fwu C-W, Chien Y-C, Kirk GD, et al. Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: Nationwide cohort study. J Natl Cancer Inst. 2009;101:1019-1072.
48. Mast EE,Margolis HS, Fiore AE, et al.A comprehensive immunization strategy to eliminate transmission of hepatitis Bvirus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: Immunization of infants, children, and adolescents.MMWRRecomm Rep. 2005; 54:1-31.